Craft
  • Home
  •  / Iovance Biotherapeutics
Iovance Biotherapeutics

Iovance Biotherapeutics

Market Capitalization

$1.7 B

2022-09-20

Iovance Biotherapeutics Summary

Company summary

Overview
Iovance Biotherapeutics (formerly Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes. The Company's lead product candidate is an autologous, ready-to-infuse cell therapy that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. In addition to metastatic melanoma, Lion's TIL technology is potentially applicable to all solid tumors, including ovarian, colorectal, head and neck, and other cancers.
Type
Public
Founded
2013
HQ
San Carlos, CA, US | view all locations
Website
http://www.iovance.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Iain Dukes, Chairman of the Board

    • Ryan Maynard, Director

      • Frederick G. Vogt, Interim CEO, President, General Counsel

      • Jean-Marc Bellemin, Chief Financial Officer

      LocationsView all

      5 locations detected

      • San Carlos, CA HQ

        United States

        999 Skyway Rd #150

      • New York, NY

        United States

        112 W 34th St

      • Philadelphia, PA

        United States

        4747 S Broad St #120

      • Philadelphia, PA

        United States

        Crescent Dr

      • Tampa, FL

        United States

        3802 Spectrum Blvd #206

      Iovance Biotherapeutics Financials

      Summary financials

      Net income (Q2, 2022)
      ($99.3M)
      Cash (Q2, 2022)
      $108.1M
      EBIT (Q2, 2022)
      ($99.7M)
      Enterprise value
      $1.6B

      Footer menu